| Patent application number | Description | Published |
|---|
| 20080269309 | PDK-1/AKT SIGNALING INHIBITORS - Use of a new class of phosphoinositide-dependent kinase-1 (PDK-1) inhibitors of formula I for inducing apoptosis in unwanted rapidly proliferating cells, for treating, inhibiting, or delaying the onset of cancer, and for preventing restenosis in a subject that has undergone an angioplasty or stent: | 10-30-2008 |
| 20080300291 | POTENT INDOLE-3-CARBINOL-DERIVED ANTITUMOR AGENTS - Compounds and methods for treating cancer and inducing apoptosis in unwanted rapidly proliferating cells. The compounds are shown in formula I: | 12-04-2008 |
| 20090048265 | NOVEL ANTITUMOR AGENTS AND METHODS OF THEIR USE - Antitumor compounds based on the α1-adrenoceptor antagonist, doxazosin, as well as compositions and methods of use. The disclosed compounds induce apoptosis in cancer cells. | 02-19-2009 |
| 20090111799 | ANTI-INFECTIVE AGENTS AGAINST INTRACELLULAR PATHOGENS - A new class of phosphoinositide-dependent kinase-1 (PDK-1) inhibitors of Formula I: | 04-30-2009 |
| 20090137679 | ZN2+Chelating Motif-Tethered Short-Chain Fatty Acids as a Novel Class of Histone Deacetylase Inhibitors | 05-28-2009 |
| 20090281328 | PDK-1/AKT SIGNALING INHIBITORS - A new class of phosphoinositide-dependent kinase-1 (PDK-1) inhibitors of formula I: | 11-12-2009 |
| 20090291992 | ANDROGEN RECEPTOR-ABLATIVE AGENTS - Compounds of the thiazolidinedione family are provided and shown to be effective androgen receptor ablative agents that can be used in methods of treating or preventing cancer or precancer, including prostate cancer. Also provided are methods of treating or preventing cancer by administering a therapeutically effective amount of one of the androgen receptor ablative agents to a subject in need of such treatment. | 11-26-2009 |
| 20100022655 | Therapeutic Agents For The Treatment Of Lymphoid Malignancies - Methods—for treatment and prevention of lymphoid malignancies, including, but not limited to acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), B-cell lymphoma, Acute Myeloid leukemia (AML), and mantle cell lymphoma (MCL). The methods include administration of a therapeutically effective amount of FTY720 (2-Amino-2-[2-(4-octylphenyl)ethyl]propane 1,3-diol hydrochloride) or a derivative, pharmaceutically acceptable salt thereof, or a prodrug thereof to a subject. | 01-28-2010 |
| 20100168184 | SMALL MOLECULE BCL-X1/BCL-2 BINDING INHIBITORS - Bcl-xL/Bcl-2 binding inhibitors useful in the treatment of unwanted proliferating cells, including cancers and precancers, in subjects in need of such treatment. Also provided are methods of treating a subject having unwanted proliferating cells comprising administering a therapeutically effective amount of a Bcl-xL/Bcl-2 binding inhibitor described herein to a subject in need of such treatment. Also provided are methods of preventing the proliferation of unwanted proliferating cells, such as cancers and precancers, in a subject comprising the step of administering a therapeutically effective amount of a Bcl-xL/Bcl-2 binding inhibitor described herein to a subject at risk of developing a condition characterized by unwanted proliferating cells. | 07-01-2010 |
| 20100267673 | PROTEIN PHOSPHATASE 2A-ACTIVATING AGENTS - Tocopheryl succinate derivatives according to formula I: | 10-21-2010 |
| 20100267820 | ANTIADHESION AGENTS - Vitamin E succinate derivatives according to formula I: | 10-21-2010 |
| 20100273871 | ANTICANCER TOCOPHERYL SUCCINATE DERIVATIVES - Compounds of formula I: | 10-28-2010 |
| 20110015242 | PDK-1/AKT SIGNALING INHIBITORS - Use of a new class of phosphoinositide-dependent kinase-1 (PDK-1) inhibitors of formula I for inducing apoptosis in unwanted rapidly proliferating cells, for treating, inhibiting, or delaying the onset of cancer, and for preventing restenosis in a subject that has undergone an angioplasty or stent: | 01-20-2011 |
| 20110054002 | ALKYL INDOLE-3-CARBINOL-DERIVED ANTITUMOR AGENTS - Compounds and methods for treating cancer or inducing apoptosis in proliferating cells. The compounds are shown in formula I: | 03-03-2011 |
| 20110086895 | THIAZOLIDINEDIONE ENERGY RESTRICTION-MIMETIC AGENTS - A method of inhibiting glycolysis in a subject by administering a pharmaceutical composition including a thiazolidinedione derivative to the subject is described. The thiazolidinedione derivatives are effective energy restriction mimetic agents, and can therefore be used to treat or prevent cancer in a subject, treat metabolic disorder, or increase the longevity of a subject. Various thiazolidinedione derivatives are also suitable for activating adenosine phosphate-activated protein kinase or inhibiting IL-6 expression. | 04-14-2011 |
